PMID- 35136740
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2230-8210 (Print)
IS  - 2230-9500 (Electronic)
IS  - 2230-9500 (Linking)
VI  - 25
IP  - 4
DP  - 2021 Jul-Aug
TI  - Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- 
      Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.
PG  - 326-331
LID - 10.4103/ijem.ijem_276_21 [doi]
AB  - OBJECTIVE: To compare the safety and efficacy of glimepiride and vildagliptin as 
      add-on therapy to metformin in newly diagnosed patients with type 2 diabetes 
      mellitus (T2DM). METHODS: This 24-week, prospective, comparative, observational 
      study was conducted among newly diagnosed patients with T2DM. The primary 
      endpoint was a change in fasting plasma glucose (FPG), postpradinal glucose 
      (PPG), and HbA1c from the baseline to week 24. The key secondary endpoints were 
      monitoring treatment-emergent adverse events such as hypoglycemia, overall 
      gastrointestinal symptoms and weight gain, and electrocardiogram (ECG) findings. 
      RESULTS: A total of 100 eligible patients were divided into two groups: group A 
      (n = 50) received vildagliptin plus metformin and group B (n = 50) received 
      glimepiride plus metformin. The mean age of the patients was 49.98 years and 
      52.12 years in group A and group B, respectively. Electrocardiographic findings 
      were within normal limits in all the patients from group A, whereas 47 patients 
      from group B showed normal ECG findings. A significant decrease in HbA1c, fasting 
      and post-prandial plasma glucose was observed with group A and group B from the 
      baseline to week-24. However, at week-24, reduction in HbA1c and blood glucose 
      parameters were comparable between the groups. Safety outcomes did not show any 
      events of hypoglycemia with vildagliptin. Mild hypoglycemia was reported with 
      glimepiride in five patients. CONCLUSION: Vildagliptin-metformin appeared to be 
      equally effective to glimepiride-metformin in reducing HbA1c level and blood 
      glucose parameters, however, resulted in better adverse event profiles with lower 
      risks of hypoglycemia.
CI  - Copyright: (c) 2021 Indian Journal of Endocrinology and Metabolism.
FAU - Kumar, Surendra
AU  - Kumar S
AD  - Department of Endocrinology, Patna Medical College, Patna, Bihar, India.
LA  - eng
PT  - Journal Article
DEP - 20211215
PL  - India
TA  - Indian J Endocrinol Metab
JT  - Indian journal of endocrinology and metabolism
JID - 101555690
PMC - PMC8793962
OTO - NOTNLM
OT  - DPP-4 inhibitor
OT  - glucose-lowering effect
OT  - hypoglycemia
OT  - initial combination therapy
COIS- There are no conflicts of interest.
EDAT- 2022/02/10 06:00
MHDA- 2022/02/10 06:01
PMCR- 2021/07/01
CRDT- 2022/02/09 05:55
PHST- 2021/06/17 00:00 [received]
PHST- 2021/08/24 00:00 [accepted]
PHST- 2022/02/09 05:55 [entrez]
PHST- 2022/02/10 06:00 [pubmed]
PHST- 2022/02/10 06:01 [medline]
PHST- 2021/07/01 00:00 [pmc-release]
AID - IJEM-25-326 [pii]
AID - 10.4103/ijem.ijem_276_21 [doi]
PST - ppublish
SO  - Indian J Endocrinol Metab. 2021 Jul-Aug;25(4):326-331. doi: 
      10.4103/ijem.ijem_276_21. Epub 2021 Dec 15.